AIM Operating Margin from 2010 to 2026
| AIM Stock | USD 1.25 0.46 58.23% |
Check AIM ImmunoTech financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among AIM ImmunoTech's main balance sheet or income statement drivers, such as Depreciation And Amortization of 210.3 K, Total Revenue of 145.3 K or Gross Profit of 131.4 K, as well as many indicators such as Price To Sales Ratio of 187, Dividend Yield of 0.0 or Days Sales Outstanding of 2 K. AIM financial statements analysis is a perfect complement when working with AIM ImmunoTech Valuation or Volatility modules.
AIM | Operating Margin | Build AI portfolio with AIM Stock |
Evaluating AIM ImmunoTech's Operating Margin across multiple reporting periods reveals the company's ability to sustain growth and manage resources effectively. This longitudinal analysis highlights inflection points, cyclical patterns, and structural changes that short-term snapshots might miss, offering deeper insight into AIM ImmunoTech's fundamental strength.
Latest AIM ImmunoTech's Operating Margin Growth Pattern
Below is the plot of the Operating Profit Margin of AIM ImmunoTech over the last few years. It is AIM ImmunoTech's Operating Profit Margin historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in AIM ImmunoTech's overall financial position and show how it may be relating to other accounts over time.
| View | Last Reported (94.12) % | 10 Years Trend |
|
Operating Profit Margin |
| Timeline |
AIM Operating Margin Regression Statistics
| Arithmetic Mean | (99.89) | |
| Coefficient Of Variation | (43.61) | |
| Mean Deviation | 32.74 | |
| Median | (114.45) | |
| Standard Deviation | 43.56 | |
| Sample Variance | 1,897 | |
| Range | 150 | |
| R-Value | (0.49) | |
| Mean Square Error | 1,530 | |
| R-Squared | 0.24 | |
| Significance | 0.04 | |
| Slope | (4.26) | |
| Total Sum of Squares | 30,359 |
AIM Operating Margin History
About AIM ImmunoTech Financial Statements
AIM ImmunoTech investors utilize fundamental indicators, such as Operating Margin, to predict how AIM Stock might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.
AIM ImmunoTech Inc., an immuno-pharma company, focuses on the research and development of therapeutics to treat multiple types of cancers, viral diseases, and immune-deficiency disorders in the United States. AIM ImmunoTech Inc. was incorporated in 1966 and is headquartered in Ocala, Florida. Aim Immunotech operates under Biotechnology classification in the United States and is traded on AMEX Exchange. It employs 21 people.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Prophet is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ProphetCheck out the analysis of AIM ImmunoTech Correlation against competitors. To learn how to invest in AIM Stock, please use our How to Invest in AIM ImmunoTech guide.You can also try the Portfolio Dashboard module to portfolio dashboard that provides centralized access to all your investments.
Will Biotechnology sector continue expanding? Could AIM diversify its offerings? Factors like these will boost the valuation of AIM ImmunoTech. If investors know AIM will grow in the future, the company's valuation will be higher. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every AIM ImmunoTech data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Earnings Share (18.16) | Revenue Per Share | Quarterly Revenue Growth (0.26) | Return On Assets | Return On Equity |
AIM ImmunoTech's market price often diverges from its book value, the accounting figure shown on AIM's balance sheet. Smart investors calculate AIM ImmunoTech's intrinsic value - its true economic worth - which may differ significantly from both market price and book value. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. Since AIM ImmunoTech's trading price responds to investor sentiment, macroeconomic conditions, and market psychology, it can swing far from fundamental value.
Understanding that AIM ImmunoTech's value differs from its trading price is crucial, as each reflects different aspects of the company. Evaluating whether AIM ImmunoTech represents a sound investment requires analyzing earnings trends, revenue growth, technical signals, industry dynamics, and expert forecasts. However, AIM ImmunoTech's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.